期刊
ANTIVIRAL RESEARCH
卷 89, 期 1, 页码 71-74出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2010.11.008
关键词
Dengue; Antibody; Enhancement; Peptide; Entry; Inhibitor
资金
- Defense Threat Reduction Agency [HDTRA1-08-1-0003, HDTRA1-09-1-0004]
- Florida Biodefense Research Consortium [W911SR-07-C-0084]
- NATIONAL LIBRARY OF MEDICINE [DP1LM011509] Funding Source: NIH RePORTER
Severe dengue virus (DENV) disease symptoms, including dengue hemorrhagic fever and dengue shock syndrome, have been correlated with the presence of pre-existing antibodies that enhance rather than neutralize infections in Fc receptor bearing cells. These antibodies can originate from previous infection with a different serotype of dengue, or from waning antibody titers that occur in infants and young children as they are weaned from breast milk that contains protective dengue-specific antibodies. Despite the apparent importance of this antibody dependent enhancement (ADE) effect, there has been no description of any specific inhibitors of this process. We explored DENV entry inhibitors as a potential strategy to block ADE. Two different peptide entry inhibitors were tested for the ability to block antibody-mediated DENV-2 infection of human. FcRII bearing K562 cells in vitro. Both peptides were able to inhibit ADE, showing that entry inhibitors are possible candidates for the development of specific treatment for severe DENV infection. (C) 2010 Elsevier BM. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据